JP2013500840A - 光力学療法を使用する癌の治療 - Google Patents
光力学療法を使用する癌の治療 Download PDFInfo
- Publication number
- JP2013500840A JP2013500840A JP2012523972A JP2012523972A JP2013500840A JP 2013500840 A JP2013500840 A JP 2013500840A JP 2012523972 A JP2012523972 A JP 2012523972A JP 2012523972 A JP2012523972 A JP 2012523972A JP 2013500840 A JP2013500840 A JP 2013500840A
- Authority
- JP
- Japan
- Prior art keywords
- hpph
- treatment
- tissue
- cancer
- normal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 39
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 238000002428 photodynamic therapy Methods 0.000 title description 25
- PUUBADHCONCMPA-USOGPTGWSA-N 3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6[C@H]([C@@H](C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C PUUBADHCONCMPA-USOGPTGWSA-N 0.000 claims abstract description 41
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 7
- 238000010521 absorption reaction Methods 0.000 claims abstract description 4
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 54
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 26
- 229960004293 porfimer sodium Drugs 0.000 description 26
- 230000003211 malignant effect Effects 0.000 description 12
- 230000006378 damage Effects 0.000 description 9
- 239000003504 photosensitizing agent Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 210000000867 larynx Anatomy 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000004101 esophageal cancer Diseases 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 4
- 206010023825 Laryngeal cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 208000017983 photosensitivity disease Diseases 0.000 description 3
- 231100000434 photosensitization Toxicity 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001260 vocal cord Anatomy 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000024312 invasive carcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010066054 Dysmorphism Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000007217 Esophageal Stenosis Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010050171 Oesophageal dysplasia Diseases 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 201000007698 cell type cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- -1 porphyrin compounds Chemical class 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0604—Lungs and/or airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、2009年8月6日に出願された米国特許出願第12/462,606号からの優先権を主張する。
(連邦支援研究に関する声明)
本発明は、米国国立衛生研究所(National Institute of Health)認可番号NIH (1R21 CA109914-01、CA 55792およびCAPO155791)による助成によってなされた。米国政府は、本発明における一定の権利を有する。
特に上気道系における重篤な癌は、通常、扁平上皮細胞タイプの癌であり、治療しない限りほぼ常に致死的であり、治療したとしても、治療は必ずしも有効ではなく、多くの場合外観が損なわれる。
比較的新しく且つ良く試験されているテトラピロール化合物は、2‐(1‐ヘキシルオキシエチル)‐2‐デビニルピロフェオホルビド‐a (HPPH)である。HPPHは、本明細書において使用するとき、遊離酸、酸塩形および各種エステルとしての2‐(1‐ヘキシルオキシエチル)‐2‐デビニルピロフェオホルビド‐aを意味する。この化合物は、腫瘍親和性であり、ニューヨーク州バッファローのRoswell Park Cancer Instituteにおいて第I/II相ヒト臨床試験を受けている。
生理学的に適合性のある媒質中のHPPHを、上記癌組織を有する患者に、3〜5mg/m2体表面積の投与量で注入する処置;
24〜60時間待機してHPPHの上記癌組織中への優先吸収を可能にする処置;および、
上記癌組織を、約665±5nmの波長の光に約75〜約200ジュール/cmのエネルギーで暴露させる処置。
また、本発明は、上記の方法において使用するHPPHも包含する。
このことは、HPPHを上気道領域の上皮タイプの組織中の癌の治療において特異的に適格化するポルフィマーナトリウムとHPPHとの重要な差異である。
注入後24時間でのデータを使用した。この時間が、マウスを一般的には非熱線量率のレーザーからの光によって処置した時間であるためである。
患者におけるHPPHは、生理学的に適合性のある媒質中で1時間に亘って注入した。
暴露は、レーザーが発出する非熱レーザー光を搬送する光ファイバーを使用して行う。レーザーは、所望の波長およびエネルギーの光を発出する任意の適切なレーザー、例えば、染料またはダイオードであり得る。暴露は、暴露の時間長および/または光強度の調整によって調整し得る。
以下、HPPH‐PDTによる上気道系の癌の予備的治療結果の下記の実施例により、本発明を例示する。
彼は、手術と放射線療法を拒絶し、HPPH (2‐[1‐ヘキシルオキシエチル]‐2‐デビニルピロフェオホルビド‐a)を使用する光力学療法治療を選択した。彼は、4mg/m2 (約0.1mg/kg)のHPPHを1時間に亘って注入された。翌日、彼は、665nmの非熱低出力レーザー光治療(150mw/cm)を受けて光力学プロセスを活性化させた。光は、喉頭鏡によってたどる1本の石英繊維によって送られた。彼は、50ジュール/cmの上記665nm光を5.5分に亘って受けた。彼は、一過性の浮腫と、治療後の最初のフォローアップ検診30日中に完全に消散した嗄声とを発症した。彼は、皮膚光増感を示さなかった。3ヶ月間の第2フォローアップ検診において、彼は、治療に対して完全な応答を有していることが判明した。正常組織に対する影響は認められなかった。
彼は、手術または放射線治療よりはむしろHPPH (2‐[1‐ヘキシルオキシエチル]‐2‐デビニルピロフェオホルビド‐a)による光力学療法治療を受けることを選択した。彼は、4mg/m2のHPPHを注入された。翌日、彼は、665nmの非熱低出力レーザー光治療(150mw/cm)を受けて光力学プロセスを活性化させた。光は、喉頭鏡によってたどる1本の石英繊維によって送られた。彼は、50ジュール/cmの上記665nm光を5.5分に亘って受けた。彼は、鎮痛薬によって制御した治療部位の一過性の中度の疼痛を発症した。この疼痛は、治療後30日間の検診時に消散した。彼は、皮膚光増感を示さなかった。6ヶ月間のフォローアップにおいて、彼は、生検によって確認された治療に対する完全な応答を有していることが判明した。正常組織に対する影響は認められなかった。
Claims (4)
- 上気道系の癌組織の治療用HPPHであって、以下
生理学的に適合性のある媒質中のHPPHを、前記癌組織を有する患者に、3〜5mg/m2体表面積の量で注入する処置、
24〜60時間待機してHPPHの前記癌組織中への優先吸収を可能にする処置、および、
前記癌組織を、約665±5nmの波長の光に約75〜約200ジュール/cmのエネルギーで暴露させる処置、
によることを特徴とするHPPH。 - HPPHの投与量レベルが、3.5〜4.0mg/m2である、請求項1記載の癌組織の治療用HPPH。
- 前記エネルギーが、約75〜約150ジュール/cmである、請求項1記載の癌組織の治療用HPPH。
- 前記癌組織が、上皮の癌組織である、請求項1記載の癌組織の治療用HPPH。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/462,606 | 2009-08-06 | ||
US12/462,606 US20100056983A1 (en) | 2007-09-27 | 2009-08-06 | Treatment of cancer using photodynamic therapy |
PCT/US2010/044677 WO2011017597A1 (en) | 2009-08-06 | 2010-08-06 | Treatment of cancer using photodynamic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013500840A true JP2013500840A (ja) | 2013-01-10 |
JP2013500840A5 JP2013500840A5 (ja) | 2013-04-25 |
Family
ID=41726451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012523972A Pending JP2013500840A (ja) | 2009-08-06 | 2010-08-06 | 光力学療法を使用する癌の治療 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100056983A1 (ja) |
EP (1) | EP2437847A4 (ja) |
JP (1) | JP2013500840A (ja) |
KR (1) | KR20120055604A (ja) |
CN (1) | CN102470239A (ja) |
CA (1) | CA2761181A1 (ja) |
WO (1) | WO2011017597A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056983A1 (en) * | 2007-09-27 | 2010-03-04 | Health Research, Inc. | Treatment of cancer using photodynamic therapy |
CN103961323B (zh) * | 2013-02-05 | 2017-10-17 | 浙江海正药业股份有限公司 | 一种注射用hpph冻干粉针制剂及其制备方法 |
CA2917545C (en) * | 2013-07-12 | 2022-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery |
CN104306326B (zh) * | 2014-09-25 | 2016-10-05 | 江苏红豆杉药业有限公司 | 含有hpph的水性药物组合物和注射液 |
KR102022763B1 (ko) | 2017-06-23 | 2019-09-19 | 중앙대학교 산학협력단 | 광화학 병용 치료를 위한 pH 반응성 고분자 복합체 및 이의 제조방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6113A (ja) * | 1982-09-27 | 1986-01-06 | ヘルス・リサーチ・インコーポレーテツド | 腫瘍治療用感光性薬物、その製造方法および装置 |
JP2004043471A (ja) * | 2002-07-11 | 2004-02-12 | Health Res Inc | 患部組織への薬物送達を補助するために血管の透過性を増強させるための光線力学療法 |
JP2005526863A (ja) * | 2001-10-17 | 2005-09-08 | マリンクロッド・インコーポレイテッド | 腫瘍標的光学診断用−光学治療用成分 |
JP2007506757A (ja) * | 2003-09-23 | 2007-03-22 | ライト サイエンシズ コーポレイション | 光線力学療法のための結合体 |
WO2008085215A1 (en) * | 2007-01-09 | 2008-07-17 | Health Research, Inc. | Treatment of barrett's esophagus using photodynamic therapy |
WO2008085216A1 (en) * | 2007-01-09 | 2008-07-17 | Health Research, Inc. | Therapeutic hpph dosage for pdt |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198460A (en) * | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
USRE39094E1 (en) * | 1988-07-20 | 2006-05-09 | Health Research, Inc. | Pyropheophorbides and their use in photodynamic therapy |
US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
USRE38994E1 (en) * | 1988-07-20 | 2006-02-28 | Health Research, Inc. | Pyropheophorbides conjugates and their use in photodynamic therapy |
US20100137396A1 (en) * | 2007-01-09 | 2010-06-03 | Health Research, Inc | Treatment of esophageal high grade dysplasia using photodynamic therapy |
US20100056983A1 (en) * | 2007-09-27 | 2010-03-04 | Health Research, Inc. | Treatment of cancer using photodynamic therapy |
-
2009
- 2009-08-06 US US12/462,606 patent/US20100056983A1/en not_active Abandoned
-
2010
- 2010-08-06 CN CN2010800252322A patent/CN102470239A/zh active Pending
- 2010-08-06 KR KR1020127005792A patent/KR20120055604A/ko not_active Application Discontinuation
- 2010-08-06 EP EP10807216.6A patent/EP2437847A4/en not_active Withdrawn
- 2010-08-06 WO PCT/US2010/044677 patent/WO2011017597A1/en active Application Filing
- 2010-08-06 JP JP2012523972A patent/JP2013500840A/ja active Pending
- 2010-08-06 CA CA2761181A patent/CA2761181A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6113A (ja) * | 1982-09-27 | 1986-01-06 | ヘルス・リサーチ・インコーポレーテツド | 腫瘍治療用感光性薬物、その製造方法および装置 |
JP2005526863A (ja) * | 2001-10-17 | 2005-09-08 | マリンクロッド・インコーポレイテッド | 腫瘍標的光学診断用−光学治療用成分 |
JP2004043471A (ja) * | 2002-07-11 | 2004-02-12 | Health Res Inc | 患部組織への薬物送達を補助するために血管の透過性を増強させるための光線力学療法 |
JP2007506757A (ja) * | 2003-09-23 | 2007-03-22 | ライト サイエンシズ コーポレイション | 光線力学療法のための結合体 |
WO2008085215A1 (en) * | 2007-01-09 | 2008-07-17 | Health Research, Inc. | Treatment of barrett's esophagus using photodynamic therapy |
WO2008085216A1 (en) * | 2007-01-09 | 2008-07-17 | Health Research, Inc. | Therapeutic hpph dosage for pdt |
Non-Patent Citations (2)
Title |
---|
JPN6014048371; LASERS IN SURGERY AND MEDICINE VOL.18, 1996, P.157-166 * |
JPN6014048373; BRITISH JOURNAL OF CANCER VOL.82, NO.7, 2000, P.1297-1299 * |
Also Published As
Publication number | Publication date |
---|---|
KR20120055604A (ko) | 2012-05-31 |
CN102470239A (zh) | 2012-05-23 |
EP2437847A4 (en) | 2013-10-30 |
US20100056983A1 (en) | 2010-03-04 |
WO2011017597A1 (en) | 2011-02-10 |
CA2761181A1 (en) | 2011-02-10 |
EP2437847A1 (en) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2731032B2 (ja) | 光化学療法による悪性および非悪性病変の検出および治療方法 | |
Sheleg et al. | Photodynamic therapy with chlorin e6 for skin metastases of melanoma | |
Dougherty et al. | Photodynamic therapy | |
Schweitzer | PHOTOFRIN‐mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies | |
Allison et al. | Oncologic photodynamic therapy photosensitizers: a clinical review | |
Gomer et al. | The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis | |
JP2003508124A (ja) | 長期間光活性化癌治療 | |
JP2009542801A (ja) | インドール−3−アルキルカルボン酸を含む光感作剤、及びこれを含む光線力学治療用キット | |
Schweitzer et al. | PHOTOFRIN‐mediated photodynamic therapy for treatment of early stage (Tis‐T2N0M0) SqCCa of oral cavity and oropharynx | |
JP2013500840A (ja) | 光力学療法を使用する癌の治療 | |
EP3244928A1 (en) | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs | |
Maier et al. | Comparison of 5‐aminolaevulinic acid and porphyrin photosensitization for photodynamic therapy of malignant bronchial stenosis: A clinical pilot study | |
Privalov et al. | Five years experience of photodynamic therapy with new chlorin photosensitizer | |
US6495585B2 (en) | Method for treating hyperproliferative tissue in a mammal | |
Kübler et al. | Photodynamic therapy of head and neck cancer | |
Land | Porphyrin phototherapy of human cancer | |
EP3389716B1 (en) | Method of photodynamic therapy (pdt) for bladder cancer | |
Masumoto et al. | Tissue distribution of a new photosensitizer ATX-S10Na (II) and effect of a diode laser (670 nm) in photodynamic therapy | |
US20100130909A1 (en) | Treatment of barrett's esophagus using photodynamic therapy | |
Lindenmann et al. | Photodynamic therapy for esophageal carcinoma | |
US20100137396A1 (en) | Treatment of esophageal high grade dysplasia using photodynamic therapy | |
WO2008085216A1 (en) | Therapeutic hpph dosage for pdt | |
Kato et al. | Photodynamic therapy in lung cancer | |
Schweitzer | Photodynamic therapy--1994: treatment of benign and malignant upper aerodigestive tract disease | |
Yazdian-Robati et al. | Photodynamic therapy for pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130305 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130305 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150527 |